Login
$CAMP
$3.86 +$0.06 (1.58%) Live

$CAMP SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 SCHEDULE 13G
05 Nov 2026 10-Q
05 Nov 2026 8-K: Financial Statements and Exhibits

Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and Argentina

05 Nov 2026 SCHEDULE 13G/A
28 Sep 2026 8-K: Regulation FD Disclosure; Other Events

On September 28, 2026, CAMP4 Therapeutics Corporation (the “Company”) held an Analyst Day meeting regarding its planned Phase 1/2 ASCEND clinical trial of CMP-002 in SYNGAP1-related disorder (the “ASCEND clinical trial”) and its pipeline...

02 Sep 2026 Form 4: Gold Kelly, Chief Financial Officer

Bought 10,000 shares ($39.6K)

31 Aug 2026 SCHEDULE 13D/A
31 Aug 2026 Form 4: Schwab Andrew J., Director

Sold 400,000 shares ($1.62M)

26 Aug 2026 Form 4: Schwab Andrew J., Director

Sold 10 shares ($45)

21 Aug 2026 Form 4: Schwab Andrew J., Director

Sold 45,147 shares ($215K) · Sold 114,700 shares ($521K) · Sold 32,018 shares ($144K)

19 Aug 2026 Form 4: Tardiff Daniel, Chief Scientific Officer

Sold 1,738 shares ($8.27K)

19 Aug 2026 SCHEDULE 13D/A
19 Aug 2026 144
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.

12 Aug 2026 EFFECT
12 Aug 2026 424B3

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support